Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2

Status

Completed 13Withdrawn 3Active not recruiting 3Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Advanced Nonhematological Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × sapanisertib × Clear all
NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03370302 2023-02-08

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Calithera Biosciences, Inc

Phase 1 Terminated
28 enrolled 33 charts

Advanced Nonhematological Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡